Mitsubishi Tanabe Pharma America Spotlights ALS Research at the XXVI World Congress of Neurology

News provided by

Mitsubishi Tanabe Pharma America, Inc.

Oct 16, 2023, 10:00 ET

JERSEY CITY, N.J., Oct. 16, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the XXVI World Congress of Neurology (WCN), being held virtually and in-person in Montreal, Quebec, October 15-19.

"We look forward to joining the scientific community at this year's meeting where we will highlight our latest ALS research, including findings from our real-world and clinical studies of RADICAVA ORS^® (edaravone) and RADICAVA^® (edaravone)," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "These presentations reflect the importance of combining insights from clinical and real-world settings to better understand the potential of our current treatment options and their impact on ALS."

MTPA's posters will be viewable in the Virtual Platform and onsite throughout the conference. Presentations include:

Real-World Data
A real-world analysis describing patient demographics, clinical characteristics and treatment outcomes in people with ALS being treated with intravenous (IV) RADICAVA, based on data collected from a U.S. provider of home and alternate-site infusions, will be presented, in addition to findings from an analysis of time to progression milestones in people treated with RADICAVA utilizing de-identified data from Optum's Clinformatics^® Data Mart (CDM) database.

Treatment Outcomes for Patients with Amyotrophic Lateral Sclerosis Receiving Intravenous Edaravone from a Home and Alternative-Site Infusion Provider (Agessandro Abrahão, M.D., M.Sc., Sunnybrook Health Sciences Centre)
Oral Presentation (Free Paper: Motor Neurone Disease): 3:00 p.m. – 3:12 p.m. EDT, October 16
Longer Milestone-Free Time in IV Edaravone–Treated vs Non–IV Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis: an Administrative Claims Analysis (Malgorzata Ciepielewska, M.S.; MTPA)
Poster #175

RADICAVA ORS
Study design details from the global, multi-center, double-blind, Phase 3b MT-1186-A02 study comparing two dosing regimens for oral edaravone to evaluate its long-term efficacy and safety in ALS, and its extension study, MT-1186-A04, will be shared. Additionally, 48-week safety results from the global Phase 3 multi-center, open-label clinical trial (MT-1186-A01) evaluating RADICAVA ORS in people with ALS will be presented.

Phase 3b Study Evaluating Superiority of Daily Dosing vs Approved On/Off Oral Edaravone Dosing Over 48 Weeks in Patients with Amyotrophic Lateral Sclerosis (MT-1186-A02) (Alejandro Salah, M.D., Ph.D., MBA, MHA; MTPA)
Poster #147
Phase 3b Extension Study Evaluating Superiority of Daily vs Approved On/Off Oral Edaravone Dosing in Patients With Amyotrophic Lateral Sclerosis (Alejandro Salah, M.D., Ph.D., MBA, MHA; MTPA)
Poster #148
Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients with Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (Angela Genge, M.D., FRCP; Montreal Neurological Institute and Hospital)
Poster #146

About RADICAVA^® (edaravone) and RADICAVA ORS^® (edaravone)
The U.S. Food and Drug Administration (FDA) approved RADICAVA^® (edaravone) on May 5, 2017, and the oral formulation RADICAVA ORS^® (edaravone) on May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA is administered in 28-day cycles by intravenous (IV) infusion. It takes 60 minutes to receive each 60 mg dose. For the initial cycle, the treatment is infused daily for 14 consecutive days, followed by a two-week drug-free period. All cycles thereafter are infused daily for 10 days within a 14-day period, followed by a two-week drug-free period. RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.^¹

Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. (MTPA). The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT^® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021) and Malaysia (December 2021). Marketing authorization for RADICAVA^® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and RADICUT^® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. To date, in the U.S., RADICAVA and RADICAVA ORS have been used to treat over 12,000 people with ALS, with over 1.57-million days of therapy, and have been prescribed by over 2,200 HCPs.^{^2-}^⁴

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.

Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.

Adverse Reactions
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.

Pregnancy
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).

For more information, including full Prescribing Information, please visit www.RADICAVA.com.

About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit www.mt-pharma-america.com or follow us on X (formerly Twitter), Facebook and LinkedIn.

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction and additionally working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to https://www.mt-pharma.co.jp/e/.

Media inquiries:
[email protected]

¹ RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022.
²Data on file. Mitsubishi Tanabe Pharma America, Inc.
³Data on file. Mitsubishi Tanabe Pharma America, Inc.
⁴ Data on file. Mitsubishi Tanabe Pharma America, Inc.

SOURCE Mitsubishi Tanabe Pharma America, Inc.